Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

From patient to patient-advocate, the story of Jaime Sanchez

Jaime Sanchez has worn many hats throughout her life, but her favorite role is being a mother. She has a diverse background, having studied and worked in fields like nursing, physical therapy, criminal justice, and early elementary teacher education, as well as home-business ownership, management, waitressing, and human resources, not in chronological order.

Jaime is a volunteer hostess and graphic assistant of the show “DocToks with Dr. Forest Tennant and Friends”, offering her help in the pain and addiction communities. She dreams of the day these communities unite to stand together. She hopes all people will recognize that anyone could face similar challenges, especially due to an accident, injury, or unexpected illness.

She recently wrote an article for Daily Remedy, Pain Upon Pain.

#Forest #Tennant #chronic #pain #patient #advocacy

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!